Genentech: FDA Accepts For Review Supplemental BLA Of Xolair

Genentech, a member of Swiss drug maker Roche Holding AG (RHHBY), said that the U.S. Food and Drug Administration has accepted for review the company's supplemental Biologics License Application or sBLA to extend the indication of Xolair (omalizumab) in allergic asthma to pediatric patients.

from RTT - Biotech http://ift.tt/1OLGcWA
via IFTTT